Currently there is no vaccine to prevent this virus and no specific antiviral therapy to treat HMPV, according to the CDC.

Currently there is no vaccine to prevent this virus and no specific antiviral therapy to treat HMPV, according to the CDC.

Adults aged 75 years or older should receive an RSV protein subunit vaccine; receipt can be considered for those aged 60 to 74 years at increased risk ...

Children under two years of age hospitalized for COVID-19 are more likely to die or become seriously ill than babies with respiratory syncytial virus (RSV), according to a study published this week in ...

Invivyd, Inc. (NASDAQ:IVVD) Q4 2025 Earnings Call Transcript March 5, 2026 Invivyd, Inc. misses on earnings expectations. Reported EPS is $-0.06428 EPS, expectations were $-0.06. Operator: Good day, ...

Human metapneumovirus (HMPV), a respiratory virus with no vaccine and no targeted antiviral treatment, is among the respiratory illnesses currently going around in the United States alongside ...

12:00 p.m.: Special coverage — Live broadcast of the memorial service for Rev. Jesse Jackson 10:00 p.m.: What happens when ...

Invivyd (NASDAQ:IVVD) executives used the company’s fourth-quarter 2025 earnings call to outline progress in its COVID-19 monoclonal antibody pipeline, provide an update on commercialization of ...

Doctors are warning people to stay vigilant as a seasonal flu virus that can lead to pneumonia and bronchitis spreads in ...

Human metapneumovirus could progress to bronchitis or pneumonia. Studies also show dual diagnoses of HMPV, influenza and RSV, resulting in serious and sometimes fatal complications. Studies show ...

Less than 40% of surveyed adults view Health Secretary Kennedy as trustworthy, compared with 86% who have confidence in their ...